Sector News

Longtime GlaxoSmithKline CFO Dingemans heads for the exit

May 9, 2018
Life sciences

GlaxoSmithKline CEO Emma Walmsley has hired more than a few new executives since taking the baton from Andrew Witty. And now, she’ll have the opportunity to fill another big slot.

Wednesday, GSK said CFO Simon Dingemans would retire from the British drugmaker and step down from its board next May. The company is now kicking off a “thorough, global search”—both internal and external—to find his replacement.

Dingemans, who joined Glaxo from Goldman Sachs, has been with the company since 2011, overseeing the Big Pharma’s multibillion-dollar asset swap with Novartis in 2015. He’s also been helping Walmsley craft the company’s new strategy since she took the helm last March.

“Since joining GSK, Simon has played a very significant role in shaping the company. He has taken a consistent and sustained approach to support investment and improve operational efficiencies in all three of our global businesses,” Walmsley said in a statement, highlighting his “support and partnership” and “his counsel to me.”

Walmsley, who took over from Andrew Witty when he retired last year, replaced 40% of GSK’s top management team within her first 9 months in the top spot. So far, her most high-profile hires have included Roche veteran Hal Barron for R&D chief and former AstraZeneca executive Luke Miels for pharma head.

A slew of executive exits at Glaxo has made room for those hires, with several company leaders following Witty out the door. Last November, R&D chief Patrick Vallance took a job with the U.K. government. Earlier that year, top pharma dog Abbas Hussain’s departure made way for Miels. And before that, vaccines chairman Moncef Slaoui and ViiV head Dominique Limet both decided to say their goodbyes.

With respiratory blockbuster Advair heading toward generic competition and pressure from payers and rivals weighing on other key products, the CFO switch could come at a busy time for Glaxo. The way Dingemans sees it, though, it’s the “right time for me to take this decision.”

“With the new strategy set, we have established strong foundations to deliver improved business and financial performance,” he said in a statement.

By Carly Helfand

Source: Fierce Pharma

comments closed

Related News

July 3, 2022

Novo Nordisk joins with nursing group to highlight correlation between Type 2 diabetes and cardio risk

Life sciences

Despite atherosclerotic cardiovascular disease (ASCVD) being the leading cause of death for people with Type 2 diabetes, half of those people have no idea of this risk. Novo Nordisk has teamed up with the Preventive Cardiovascular Nurses Association (PCNA) for “Making the Connection,” a program to help increase understanding of the link between the two diseases.

July 3, 2022

First treatment for ‘broken heart syndrome’ trialled

Life sciences

The first ever treatment for broken heart syndrome – also known as Takotsubo cardiomyopathy – is to be trialled by researchers at the University of Aberdeen. Scientists will trial a programme of exercise conditioning and psychological therapy for people who have been diagnosed with the condition following a £300,000 grant from the British Heart Foundation.

July 3, 2022

Nestlé acquiring The Better Health Company in market expansion deal

Life sciences

Nestlé Health Science is set to acquire The Better Health Company (TBHC), as part of its goals to grow global market share while spurring innovation across the nutrition industry. The acquisition includes the GO Healthy brand with its vitamins and supplements, Egmont, the Manuka honey brand and New Zealand Health Manufacturing, an Auckland-based manufacturing facility for vitamins minerals and supplements.